Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 19/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.55 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097589 | 0.89 | MTOR (0.73) | MTORKCNH2PIK3CA | |
| SCHEMBL2625425 | 0.89 | MTOR (0.73) | MTORKCNH2PIK3CA | |
| SCHEMBL3718595 | 0.89 | PIK3CA (0.57) | MTORPIK3CAPIK3CGPIK3CDCYP2C8 | |
| SCHEMBL3720817 | 0.85 | MTOR (0.58) | MTORPIK3CAPIK3CGPIK3CDCYP2C8 | |
| SCHEMBL3727473 | 0.84 | PIK3CA (0.59) | MTORPIK3CAPIK3CGPIK3CDCYP2C8 | |
| SCHEMBL3725406 | 0.83 | MTOR (0.55) | MTORPIK3CAPIK3CGPIK3CDCYP2C8 | |
| SCHEMBL15196060 | 0.81 | MTOR (0.53) | MTORKCNH2PIK3CAPIK3CG | |
| SCHEMBL3729710 | 0.81 | MTOR (0.52) | MTORKCNH2PIK3CAPIK3CG | |
| SCHEMBL3722978 | 0.79 | MTOR (0.50) | MTORKCNH2PIK3CAPIK3CG | |
| SCHEMBL3723931 | 0.79 | MTOR (0.55) | MTORPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010120996-A1 | 5,6,7,8-TETRAHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-10-21 | — | — | WO | disclosed |